Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy.
Dutch Melanoma Treatment Registry
metastatic melanoma
surgery
systemic therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 May 2020
07 May 2020
Historique:
received:
06
03
2020
revised:
28
04
2020
accepted:
04
05
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
epublish
Résumé
Opportunities for surgical treatment in metastatic melanoma patients have re-emerged due to the development of novel systemic therapeutics over the past decade. The aim of this study is to present data on outcomes of surgery in patients with unresectable stage IIIC and IV melanoma, who have previously been treated with immunotherapy or targeted therapy. Data was extracted from the Dutch Melanoma Treatment Registry (DMTR) on 154 patients obtaining disease control to systemic therapy and undergoing subsequent surgery. Disease control was defined as a complete response (CR), which was seen in 3.2% of patients; a partial response (PR), seen in 46.1% of patients; or stable disease (SD), seen in 44.2% of patients. At a median follow-up of 10.0 months (interquartile range 4-22) after surgery, the median overall survival (OS) had not been reached in our cohort and median progression-free survival (PFS) was 9.0 months (95% CI 6.3-11.7). A CR or PR at first follow-up after surgery was associated with both a better OS and PFS compared to stable or progressive disease (
Identifiants
pubmed: 32392717
pii: cancers12051176
doi: 10.3390/cancers12051176
pmc: PMC7281176
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ZonMw
ID : 836002002
Références
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
J Immunother Cancer. 2019 Jul 24;7(1):196
pubmed: 31340861
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2018 Oct;19(10):1315-1327
pubmed: 30219628
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Ann Surg Oncol. 2020 Apr;27(4):1180-1188
pubmed: 31848819
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Cancer. 2011 Oct 15;117(20):4740-06
pubmed: 21455999
J Clin Oncol. 2008 Feb 1;26(4):527-34
pubmed: 18235113
Eur J Cancer. 2017 Feb;72:156-165
pubmed: 28030784
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Ann Surg Oncol. 2012 Aug;19(8):2547-55
pubmed: 22648554
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
Clin Epidemiol. 2016 May 26;8:109-22
pubmed: 27307765
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494